BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.04 by 357.14 percent. This is a 328.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $159.395 million which missed the analyst consensus estimate of $162.974 million by 2.20 percent. This is a 36.14 percent increase over sales of $117.085 million the same period last year.